Skip to main content

Advertisement

SpringerLink
Log in

Calcinosis in Juvenile Dermatomyositis—Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

We performed a systematic review of the literature on the epidemiology, pathogenesis, clinical and laboratory characterization, and treatment of calcinosis in patients with juvenile dermatomyositis (JDM). A qualitative systematic review was conducted from January 1975 to April 2023 according to the PRISMA protocol using three electronic databases: PubMed, Web of Science, and Scopus. Studies were analyzed based on the following eligibility criteria: at least one combination of the terms described in the search strategy appeared in the title, written in English, Portuguese, or Spanish, and addressed the epidemiology, pathogenesis, diagnosis, and treatment of calcinosis in juvenile dermatomyositis. Systematic or scoping reviews, letters, clinical images, book chapters, abstracts, inflammatory myopathy in other connective tissue diseases, idiopathic inflammatory myopathies in adults, and purely qualitative studies were excluded.

Recent Findings

Seventy-five studies were included. According to the literature, calcinosis is common in women, around five years old, with three years of disease in association with osteoarticular, cutaneous, pulmonary manifestations, and fever. The pathogenesis is still unknown, but the participation of interleukin 1 and 6, tumor necrosis factor alpha, and innate immunity dysregulation seem to be involved. Common autoantibodies are anti-NXP-2, anti-MDA-5, and anti-Mi-2, and their treatment remains controversial. Prospective, randomized, controlled studies are needed to evaluate treatment protocols and map the natural history of this serious complication.

Summary

Calcinosis seems to be more common in White female children with muscle weakness, fever, arthritis, severe pulmonary, and skin involvement with anti-NXP-2, anti-MDA-5, and anti-Mi-2 autoantibodies. The multitargets and aggressive treatment is recommended.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Davuluri S, Duvuri B, Lood C, Faghihi-Kashani S, Chung L. Calcinosis in dermatomyositis: Origins and possible therapeutic avenues. Best Pract Res Clin Rheumatol. 2022;36: 101768. https://doi.org/10.1016/j.berh.2022.101768.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lundberg I, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7:86. https://doi.org/10.1038/s41572-021-00321-x.

    Article  PubMed  Google Scholar 

  3. • McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and 290 Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr. Rheumatology. 2006;45:1255–60. https://doi.org/10.1093/rheumatology/kel099. This study describes a cohort that helps understand the natural history of the disease.

    Article  CAS  PubMed  Google Scholar 

  4. Clemente G, Piotto DGP, Barbosa C, et al. High frequency of calcinosis in juvenile 293 dermatomyositis: a risk factor study. Rev Bras Reumatol. 2012;52:549–53.

    Article  PubMed  Google Scholar 

  5. Chander S, Gordon P. Soft tissue and subcutaneous calcification in connective tissue diseases. Curr Opin Rheumatol. 2012;24:158–64. https://doi.org/10.1097/BOR.0b013e32834ff5cd.

    Article  CAS  PubMed  Google Scholar 

  6. Chung MP, Richardson C, Kirakossian D, et al. Calcinosis biomarkers in adult and juvenile dermatomyositis. Autoimmun Rev. 2020;19: 102533. https://doi.org/10.1016/j.autrev.2020.102533.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Elahmar H, Feldman BM, Johnson SR. Management of calcinosis cutis in rheumatic diseases. J Rheumatol. 2022;49:980–9. https://doi.org/10.3899/jrheum.211393.

    Article  CAS  PubMed  Google Scholar 

  8. Shinjo SK, Souza FH. Update on the treatment of calcinosis in dermatomyositis. Rev Bras Reumatol. 2013;53:211–4.

    PubMed  Google Scholar 

  9. Traineua H, Aggarwal R, Monfort J-B, et al. Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. J Am Acad Dermatol. 2022;82:317–25. https://doi.org/10.1016/j.jaad.2019.07.006.

    Article  CAS  Google Scholar 

  10. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–7. https://doi.org/10.1056/NEJM197502132920706.

    Article  CAS  PubMed  Google Scholar 

  11. •• Duvvuri B, Pachman LM, Hermanson P, et al. Role of mitochondria in the myopathy of juvenile dermatomyositis and implications for skeletal muscle calcinosis. J Autoimmun. 2023;138: 103061. https://doi.org/10.1016/j.jaut.2023.103061. This study highlights possible pathophysiological pathways of calcinosis in JDM.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mastrolia MV, Orsini SI, Marrani E, et al. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis. Clin Exp Rheumatol. 2023;41:402–3. https://doi.org/10.55563/clinexprheumatol/7k9ajj.

    Article  PubMed  Google Scholar 

  13. • Sener S, Basaran O, Batu ED, et al. Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature. Semin Arthritis Rheum. 2023;58: 152133. https://doi.org/10.1016/j.semarthrit.2022.152133. This study describes a cohort that helps understand the natural history of the disease.

    Article  PubMed  Google Scholar 

  14. • Cancarini P, Nozawa T, Whitney K, et al. The clinical features of juvenile dermatomyositis: A single-centre inception cohort. Semin Arthritis Rheum. 2022;57: 152104. https://doi.org/10.1016/j.semarthrit.2022.152104. This study describes a cohort that helps understand the natural history of the disease.

    Article  CAS  PubMed  Google Scholar 

  15. • El-Garf K, El-Garf A, Salah S, Marzouk H, Farag Y, Mostafa N. A juvenile dermatomyositis: demographics, characteristics and disease outcome in an Egyptian cohort. Clin Exp Rheumatol. 2022;40:450–6. https://doi.org/10.55563/clinexprheumatol/h0s7tq. This study describes a cohort that helps understand the epidemiology of the disease.

    Article  PubMed  Google Scholar 

  16. Janarthanan M, Mohan M, Murali A. Bisphosphonate therapy for juvenile dermatomyositis-associated calcinosis and metaphyseal zebra lines. BMJ Case Rep. 2022;15: e252814. https://doi.org/10.1136/bcr-2022-252814.

    Article  PubMed  Google Scholar 

  17. Jin J, Yu H. Use of adalimumab in a child with juvenile dermatomyositis and calcinosis. Indian J Pediatr. 2022;89:1270. https://doi.org/10.1007/s12098-022-04332-8.

    Article  PubMed  Google Scholar 

  18. Linan-Barroso JM, Gonzalez-Estrada A, García-Morillo JS. Therapy-resistant dermatomyositis with extensive ‘lumbar belt’ calcinosis. BMJ Case Rep. 2022;15: e249110. https://doi.org/10.1136/bcr-2022-249110.

    Article  PubMed  Google Scholar 

  19. Neely J, Long CS, Sturrock H, Kim S. Association of short-term ultraviolet radiation exposure and disease severity in juvenile dermatomyositis: results from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. Arthritis Care Res (Hoboken). 2019;71:1600–5. https://doi.org/10.1002/acr.23840.

    Article  PubMed  Google Scholar 

  20. Nitiyarom R, Charuvanji S, Likasitwattanakul S, et al. Juvenile dermatomyositis in Thai children: Retrospective review of 30 cases from a tertiary care center. Indian J Dermatol Venereol Leprol. 2023;88:162–70. https://doi.org/10.25259/IJDVL_297_20.

    Article  Google Scholar 

  21. Toplak N, Pimpale Chavan P, et al. Is Anti-NXP2 autoantibody a risk factor for calcinosis and poor outcome in juvenile dermatomyositis patients? Case Series Front Pediatr. 2022;9: 810785. https://doi.org/10.3389/fped.2021.810785.

    Article  PubMed  Google Scholar 

  22. Concannon A, Han DY. Incidence, severity and clinical manifestations of juvenile dermatomyositis among Maori and Pacific Island compared to European children. J Paediatr Child Health. 2021;57:1881–5. https://doi.org/10.1111/jpc.15595.

    Article  PubMed  Google Scholar 

  23. Chung CH. Calcinosis universalis in juvenile dermatomyositis. Chonnam Med J. 2020;56: 212213. https://doi.org/10.4068/cmj.2020.56.3.212.

    Article  Google Scholar 

  24. • Campanilho-Marques R, Deakin CT, Simou S, et al. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients. Arthritis Res Ther. 2020;22:79. https://doi.org/10.1186/s13075-020-02164-5. This study describes a cohort that helps understand the disease's response to immunobiologicals.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Giri S, Parida JR, Dash M, Panda M. pamidronate in treatment of calcinosis in juvenile dermatomyositis. Indian Pediatr. 2020;57:75–6.

    Article  PubMed  Google Scholar 

  26. Lebrón CV, Montesino MDR, Navarrete VM, Miera FJTS. Treatment with rituximab in juvenile dermatomyositis: effect on calcinosis. Reumatol Clin. 2020;16:368–70. https://doi.org/10.1016/j.reuma.2018.06.010.

    Article  Google Scholar 

  27. Moegle C, Lipsker D. Juvenile dermatomyositis: A series of 22 cases. Ann Dermatol Venereol. 2020;147:494–503. https://doi.org/10.1016/j.annder.2020.04.016.

    Article  CAS  PubMed  Google Scholar 

  28. Tsaltskan V, Aldous A, Serafi S, et al. Long-term outcomes in juvenile myositis patients. Semin Arthritis Rheum. 2020;50:149–55. https://doi.org/10.1016/j.semarthrit.2019.06.014.

    Article  PubMed  Google Scholar 

  29. Rathore U, Gupta L. Scalp calcinosis in juvenile dermatomyositis. Rheumatology. 2020;60:1569. https://doi.org/10.1093/rheumatology/keaa566.

    Article  Google Scholar 

  30. Sukumaran S, Vijayan V. Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl. Case Rep Rheumatol. 2020;28:4073879. https://doi.org/10.1155/2020/4073879.

    Article  Google Scholar 

  31. Li J, Zhou Z. Calcinosis in juvenile dermatomyositis. N Engl J Med. 2019;381: e31. https://doi.org/10.1056/nejmicm1809669.

    Article  PubMed  Google Scholar 

  32. Gupta P, Shruti S, Chaudhary V, Khullar G, Siraj F. Juvenile dermatomyositis: A case report and review of literature. Cureus. 2019;11: e3935. https://doi.org/10.7759/cureus.3935.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Çakan M, Karadağ ŞG, Ayaz NA. Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil. Turk J Pediatr. 2019;61:771–5. https://doi.org/10.24953/turkjped.2019.05.018.

    Article  PubMed  Google Scholar 

  34. • Orandi AB, Dharnidharka VR, Al-Hammadi N, et al. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis. Pediatr Rheumatol Online J. 2018;16:84. https://doi.org/10.1186/s12969-018-0299-9. This study helps understand the disease's response to immunobiologicals.

  35. Al-Mayouf SM, Al Mutiari N, Muzaffer M, et al. Phenotypic characteristics and outcome of juvenile dermatomyositis in Arab children. Rheumatol Int. 2017;37:1513–7. https://doi.org/10.1007/s00296-017-3770-x.

    Article  PubMed  Google Scholar 

  36. Barut K, Ydin POA, Adrovic A, Sahin S, Kasapcopur O. Juvenile dermatomyositis: a tertiary center experience. Clin Rheumatol. 2017;36:361–6. https://doi.org/10.1007/s10067-016-3530-4.

    Article  PubMed  Google Scholar 

  37. Grijsen ML, Mchaile D, Geult I, et al. Juvenile dermatomyositis in a 4-year-old Kenyan girl. Clin Case Rep. 2017;5:134–8. https://doi.org/10.1002/ccr3.816.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Phillippi K, Hoeltzel M, Byun Robinson A, et al. Race, income, and disease outcomes in juvenile dermatomyositis. J Pediatr. 2017;184(38–44): e1. https://doi.org/10.1016/j.jpeds.2017.01.046.

    Article  Google Scholar 

  39. Ibarra M, Rigsby C, Morgan GA, Sammet CL, et al. Monitoring change in volume of calcifications in juvenile idiopathic inflammatory myopathy: a pilot study using low dose computed tomography. Pediatr Rheumatol Online J. 2016;14:64. https://doi.org/10.1186/s12969-016-0123-3.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Okong’o LO, Esser M, Wilmshurst J, Scott C. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. Pediatr Rheumatol Online J. 2016;14:60. https://doi.org/10.1186/s12969-016-0118-0.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Saini I, Kalaivani M, Kabra SK. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome. Rheumatol Int. 2016;36:961–5. https://doi.org/10.1007/s00296-016-3467-6.

    Article  CAS  PubMed  Google Scholar 

  42. Nagar RP, Bharati J, Sheriff A, Priyadarshini P, Chumber S, Kabra SK. Calcinosis in juvenile dermatomyositis mimicking cold abscess. Natl Med J India. 2016;29:87–8.

    PubMed  Google Scholar 

  43. Tayfur AC, Topaloglu R, Gulhan B, Bilginer Y. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis. Mod Rheumatol. 2015;25:615–20. https://doi.org/10.3109/14397595.2014.988197.

    Article  CAS  PubMed  Google Scholar 

  44. Turan E, Yesilova Y, Surucu HA, et al. Juvenile dermatomyositis with joint contractures and calcinosis cutis. Dermatol Online J. 2015;21:13030/qt1cg4c5pn.

    Article  PubMed  Google Scholar 

  45. Faller G, Mistry BJ, Tikly M. Juvenile dermatomyositis in South African children is characterised by frequent dystrophic calcification: a cross sectional study. Pediatr Rheumatol Online J. 2014;12:2. https://doi.org/10.1186/1546-0096-12-2.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Martillotti J, Moote D, Zemel L. Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis. Pediatr Radiol. 2014;44:115–8. https://doi.org/10.1007/s00247-013-2738-6.

    Article  PubMed  Google Scholar 

  47. Meher BK, Mishra P, Sivaraj P, Padhan P. Severe calcinosis cutis with cutaneous ulceration in juvenile dermatomyositis. Indian Pediatr. 2014;251:925–7. https://doi.org/10.1007/s13312-014-0531-8.

    Article  Google Scholar 

  48. Pagnini I, Simonini G, Giani T, et al. Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis. Clin Exp Rheumatol. 2014;32:408–9.

    CAS  PubMed  Google Scholar 

  49. Palaniappan P, Lionel A, Kumar S. Successful treatment of calcinosis cutis in juvenile dermatomyositis with pamidronate. J Clin Rheumatol. 2014;20:454–5. https://doi.org/10.1097/rhu.0000000000000199.

    Article  PubMed  Google Scholar 

  50. Sanyal S, Atwal SS, Mondal D, Garga UC. Radiographic patterns of soft tissue calcinosis in juvenile dermatomyositis and its clinical implications. J Clin Diagn Res. 2014;8:RD08-11. https://doi.org/10.7860/JCDR/2014/10787.5321.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford). 2014;53:2204–8. https://doi.org/10.1093/rheumatology/keu259.

    Article  PubMed  Google Scholar 

  52. Gowdie PJ, Allen RC, Kornberg AJ, Akikusa JD. Clinical features and disease course of patients with juvenile dermatomyositis. Int J Rheum Dis. 2013;16:561–7. https://doi.org/10.1111/1756-185X.12107.

    Article  CAS  PubMed  Google Scholar 

  53. Prasad S, Misra R, Agarwal V, Lawrece A, Aggarwal A. Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade? Int J Rheum Dis. 2013;16:556–60. https://doi.org/10.1111/1756-185X.12053.

    Article  PubMed  Google Scholar 

  54. Toumiy M, Janani S, Rachidi W, Etaouil N, Mkinsi O. Calcinosis universalis complicating juvenile dermatomyositis: improvement after intravenous immunoglobulin therapy. Joint Bone Spine. 2013;80:108–9. https://doi.org/10.1016/j.jbspin.2012.07.001.

    Article  Google Scholar 

  55. Ya-ling L, Jing H, Qian L. A severe case of universal calcinosis with juvenile dermatomyositis. Indian J Dermatol Venereol Leprol. 2021;78:774. https://doi.org/10.4103/0378-6323.102395.

    Article  Google Scholar 

  56. Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160:520–2. https://doi.org/10.1016/j.jpeds.2011.11.057.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Cairoli E, Garra V, Bruzzone MJ, Gambini JP. Extensive calcinosis in juvenile dermatomyositis. Acta Reumatol Port. 2011;36:180–1.

    PubMed  Google Scholar 

  58. Lorenzoni PJ, Scola RH, Kay CSK, et al. Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases. Pediatr Neurol. 2011;45:17–22. https://doi.org/10.1016/j.pediatrneurol.2011.01.018.

    Article  PubMed  Google Scholar 

  59. Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheum Dis. 2010;13:e26–8. https://doi.org/10.1111/j.1756-185X.2010.01483.x.

    Article  PubMed  Google Scholar 

  60. Miyamae T, Sano F, Ozawa R, et al. Efficacy of thalidomide in a girl with inflammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol Online J. 2010;8:6. https://doi.org/10.1186/1546-0096-8-6.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Puche AM, Penades IC, Montesinos BL. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28:135–40.

    Google Scholar 

  62. Ravelli A, Trail L, Ferrari C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62:63–72. https://doi.org/10.1002/acr.20015.

    Article  PubMed  Google Scholar 

  63. Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60:3425–35. https://doi.org/10.1002/art.24904.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Joint Bone Spine. 2010;77:70–2. https://doi.org/10.1016/j.jbspin.2009.04.011.

    Article  PubMed  Google Scholar 

  65. Sato JO, Sallum AME, Ferriani VPL, et al. A Brazilian registry of juvenile dermatomyositis: onset features and classification of 189 cases. Clin Exp Rheumatol. 2009;27:1031–8.

    CAS  PubMed  Google Scholar 

  66. Ayala ZM, Ramírez RM, Zerón SM, Fuentes EF, Velázquez RM. Dermatomiositis juvenil y calcinosis extensa. Tratamiento con metilprednisolona y metotrexato. Reumatol Clin. 2008;4:248–50. https://doi.org/10.1016/S1699-258X(08)75546-3.

    Article  Google Scholar 

  67. Riley P, McCann LJ, Maillard SM, et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47:877–80. https://doi.org/10.1093/rheumatology/ken074.

    Article  CAS  PubMed  Google Scholar 

  68. Jat KR, Singh S. Calcinosis in juvenile dermatomyositis. Indian Pediatr. 2008;45:784.

    PubMed  Google Scholar 

  69. Salum AME, Pivato FCMM, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr. 2008;84:68–74. https://doi.org/10.2223/JPED.1746.

    Article  Google Scholar 

  70. Wu JJ, Metz BJ. Calcinosis cutis of juvenile dermatomyositis treated with incision and drainage. Dermatol Surg. 2008;34:575–7. https://doi.org/10.1111/j.1524-4725.2007.34106.x.

    Article  CAS  PubMed  Google Scholar 

  71. Constatin T, Ponyi A, Orbán I, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary-clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006;39:223–32. https://doi.org/10.1080/08916930600622819.

    Article  Google Scholar 

  72. Chiu SK, Yang YH, Wang LC, Chiang BL. Ten-year experience of juvenile dermatomyositis: a retrospective study. J Microbiol Immunol Infect. 2007;40:68–73.

    PubMed  Google Scholar 

  73. Pachman LM, Veis A, Stock S, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum. 2006;54:3345–50. https://doi.org/10.1002/art.22158.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Singh S, Bansal A. Twelve years experience of juvenile dermatomyositis in North India. Rheumatol Int. 2006;26:510–5. https://doi.org/10.1007/s00296-005-0030-2.

    Article  PubMed  Google Scholar 

  75. Briso-Montiano ME, Sánchez PS, Velasco MB, et al. Juvenile amyopathic dermatomyositis and calcinosis. An Pediatr (Barc). 2005;62:286–8. https://doi.org/10.1157/13071846.

    Article  Google Scholar 

  76. Sallum AM, Kiss MHB, Sachetti S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr. 2022;60:889–99. https://doi.org/10.1590/S0004-282X2002000600001.

    Article  Google Scholar 

  77. Harel L, Harel G, Korenreich L, Straussberg R, Amir J. Treatment of calcinosis in juvenile dermatomyositis with probenecid: the role of phosphorus metabolism in the development of calcifications. J Rheumatol. 2001;28:1129–32.

    CAS  PubMed  Google Scholar 

  78. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138:763–6. https://doi.org/10.1067/mpd.2001.112473.

    Article  CAS  PubMed  Google Scholar 

  79. •• Huber AM, Lang B, LeBlanc CM, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum. 2000;43:541–9. https://doi.org/10.1002/1529-0131(200003)43:3%3c541::AID-ANR9%3e3.0.CO;2-T. This study describes a cohort that helps understand the natural history of the disease.

    Article  CAS  PubMed  Google Scholar 

  80. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25:1198–204.

    CAS  PubMed  Google Scholar 

  81. Kobayashi S, Higuchi K, Tamaki H, et al. Characteristics of juvenile dermatomyositis in Japan. Pediatr Int. 1997;39:257–62. https://doi.org/10.1111/j.1442-200x.1997.tb03595.x.

    Article  CAS  Google Scholar 

  82. Wanakul S, Pongprasit P, Wattakankrai P. Calcinosis cutis presenting years before other clinical manifestations of juvenile dermatomyositis: report of two cases. Australas J Dermatol. 1997;38:202–5. https://doi.org/10.1111/j.1440-0960.1997.tb01698.x.

    Article  Google Scholar 

  83. Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23:2152–5.

    CAS  PubMed  Google Scholar 

  84. Nakagawa T, Taikawa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol. 1993;20:558–90. https://doi.org/10.1111/j.1346-8138.1993.tb01338.x.

    Article  CAS  PubMed  Google Scholar 

  85. Agud-Dios M, Arroyo-Andres J, Rubio-Muñiz C, et al. Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy. Dermatol Ther. 2022;35: e15960. https://doi.org/10.1111/dth.15960.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors have received no funding.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de São Paulo, R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo, SP, 05403-010, Brazil

    Jucier Gonçalves Júnior & Samuel Katsuyuki Shinjo

  2. Faculdade de Medicina, Universidade Federal Cariri, UFCA, Barbalha, CE, Brazil

    Jucier Gonçalves Júnior

Authors
  1. Jucier Gonçalves Júnior
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel Katsuyuki Shinjo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors carried out the collection, analysis, discussion and final appreciation of the paper.

Corresponding author

Correspondence to Jucier Gonçalves Júnior.

Ethics declarations

Human and Animal Rights Statement

This article does not contain any studies with human or animal subjects performed by any of the authors.

Conflict of Interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonçalves Júnior, J., Shinjo, S.K. Calcinosis in Juvenile Dermatomyositis—Epidemiology, Pathogenesis, Clinical Features, and Treatment: A Systematic Review. Curr Rheumatol Rep 26, 53–68 (2024). https://doi.org/10.1007/s11926-023-01126-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-023-01126-5

Keywords

Search

Navigation